Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain

Marilyn R. Semenchuk, Scott J Sherman, Bennet Davis

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

Objective: To evaluate the effectiveness and safety of bupropion sustained-release (SR) for the treatment of neuropathic pain. Methods: This single-center, outpatient, randomized, double-blind, placebo-controlled, crossover study consisted of two phases. Forty-one nondepressed patients with neuropathic pain spent 6 weeks in each phase in random order and received identical tablets of 150 mg bupropion SR or placebo. Patients were instructed to take one tablet once daily for 1 week followed by one tablet twice daily for 5 weeks. Results: While the patients took bupropion SR, neuropathic pain relief was improved or much improved in 30 (73%) patients, and one of these patients became pain-free. The mean average pain score at baseline was 5.7, which remained unchanged at the end of week 6 with placebo, but decreased by 1.7 points to 4.0 (p < 0.001) during therapy with bupropion SR. Pain relief with bupropion SR was significant at week 2 (p < 0.05) and continued throughout weeks 3 through 6 (p < 0.001). A significant decrease in interference of pain on quality of life was observed while patients were receiving bupropion SR compared with placebo. Side effects experienced with bupropion SR were not dose-limiting and consisted primarily of dry mouth, insomnia, headache, gastrointestinal upset, tremor, constipation, and dizziness. Conclusion: This placebo-controlled crossover trial showed that bupropion SR (150-300 mg daily) was effective and well tolerated for the treatment of neuropathic pain.

Original languageEnglish (US)
Pages (from-to)1583-1588
Number of pages6
JournalNeurology
Volume57
Issue number9
StatePublished - Nov 13 2001

Fingerprint

Bupropion
Neuralgia
Placebos
Tablets
Therapeutics
Pain
Cross-Over Studies
Sleep Initiation and Maintenance Disorders
Dizziness
Tremor
Constipation
Headache
Mouth
Outpatients
Quality of Life
Safety

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. / Semenchuk, Marilyn R.; Sherman, Scott J; Davis, Bennet.

In: Neurology, Vol. 57, No. 9, 13.11.2001, p. 1583-1588.

Research output: Contribution to journalArticle

Semenchuk, Marilyn R. ; Sherman, Scott J ; Davis, Bennet. / Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. In: Neurology. 2001 ; Vol. 57, No. 9. pp. 1583-1588.
@article{495babbdbf0142a98235eda764de77d8,
title = "Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain",
abstract = "Objective: To evaluate the effectiveness and safety of bupropion sustained-release (SR) for the treatment of neuropathic pain. Methods: This single-center, outpatient, randomized, double-blind, placebo-controlled, crossover study consisted of two phases. Forty-one nondepressed patients with neuropathic pain spent 6 weeks in each phase in random order and received identical tablets of 150 mg bupropion SR or placebo. Patients were instructed to take one tablet once daily for 1 week followed by one tablet twice daily for 5 weeks. Results: While the patients took bupropion SR, neuropathic pain relief was improved or much improved in 30 (73{\%}) patients, and one of these patients became pain-free. The mean average pain score at baseline was 5.7, which remained unchanged at the end of week 6 with placebo, but decreased by 1.7 points to 4.0 (p < 0.001) during therapy with bupropion SR. Pain relief with bupropion SR was significant at week 2 (p < 0.05) and continued throughout weeks 3 through 6 (p < 0.001). A significant decrease in interference of pain on quality of life was observed while patients were receiving bupropion SR compared with placebo. Side effects experienced with bupropion SR were not dose-limiting and consisted primarily of dry mouth, insomnia, headache, gastrointestinal upset, tremor, constipation, and dizziness. Conclusion: This placebo-controlled crossover trial showed that bupropion SR (150-300 mg daily) was effective and well tolerated for the treatment of neuropathic pain.",
author = "Semenchuk, {Marilyn R.} and Sherman, {Scott J} and Bennet Davis",
year = "2001",
month = "11",
day = "13",
language = "English (US)",
volume = "57",
pages = "1583--1588",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain

AU - Semenchuk, Marilyn R.

AU - Sherman, Scott J

AU - Davis, Bennet

PY - 2001/11/13

Y1 - 2001/11/13

N2 - Objective: To evaluate the effectiveness and safety of bupropion sustained-release (SR) for the treatment of neuropathic pain. Methods: This single-center, outpatient, randomized, double-blind, placebo-controlled, crossover study consisted of two phases. Forty-one nondepressed patients with neuropathic pain spent 6 weeks in each phase in random order and received identical tablets of 150 mg bupropion SR or placebo. Patients were instructed to take one tablet once daily for 1 week followed by one tablet twice daily for 5 weeks. Results: While the patients took bupropion SR, neuropathic pain relief was improved or much improved in 30 (73%) patients, and one of these patients became pain-free. The mean average pain score at baseline was 5.7, which remained unchanged at the end of week 6 with placebo, but decreased by 1.7 points to 4.0 (p < 0.001) during therapy with bupropion SR. Pain relief with bupropion SR was significant at week 2 (p < 0.05) and continued throughout weeks 3 through 6 (p < 0.001). A significant decrease in interference of pain on quality of life was observed while patients were receiving bupropion SR compared with placebo. Side effects experienced with bupropion SR were not dose-limiting and consisted primarily of dry mouth, insomnia, headache, gastrointestinal upset, tremor, constipation, and dizziness. Conclusion: This placebo-controlled crossover trial showed that bupropion SR (150-300 mg daily) was effective and well tolerated for the treatment of neuropathic pain.

AB - Objective: To evaluate the effectiveness and safety of bupropion sustained-release (SR) for the treatment of neuropathic pain. Methods: This single-center, outpatient, randomized, double-blind, placebo-controlled, crossover study consisted of two phases. Forty-one nondepressed patients with neuropathic pain spent 6 weeks in each phase in random order and received identical tablets of 150 mg bupropion SR or placebo. Patients were instructed to take one tablet once daily for 1 week followed by one tablet twice daily for 5 weeks. Results: While the patients took bupropion SR, neuropathic pain relief was improved or much improved in 30 (73%) patients, and one of these patients became pain-free. The mean average pain score at baseline was 5.7, which remained unchanged at the end of week 6 with placebo, but decreased by 1.7 points to 4.0 (p < 0.001) during therapy with bupropion SR. Pain relief with bupropion SR was significant at week 2 (p < 0.05) and continued throughout weeks 3 through 6 (p < 0.001). A significant decrease in interference of pain on quality of life was observed while patients were receiving bupropion SR compared with placebo. Side effects experienced with bupropion SR were not dose-limiting and consisted primarily of dry mouth, insomnia, headache, gastrointestinal upset, tremor, constipation, and dizziness. Conclusion: This placebo-controlled crossover trial showed that bupropion SR (150-300 mg daily) was effective and well tolerated for the treatment of neuropathic pain.

UR - http://www.scopus.com/inward/record.url?scp=0035856415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035856415&partnerID=8YFLogxK

M3 - Article

C2 - 11706096

AN - SCOPUS:0035856415

VL - 57

SP - 1583

EP - 1588

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 9

ER -